MedTrace Logo

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

NCT05096728 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2023-12-22

No results posted yet for this study

Summary

The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be approached for consent when they are placed on 30mg of Nifedipine daily by their primary provider and will be enrolled in the study when the primary provider has made the decision to increase the patient's daily dose of Nifedipine XL from 30mg to 60mg.

Conditions

  • Preeclampsia With Severe Features

Interventions

DRUG

Nifedipine XL

Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups * Once daily Nifedipine XL 60mg Vs. * Twice daily Nifedipine XL 30mg

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Kara Rood, MD · Ohio State University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-12-06
Completion
2023-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05096728 on ClinicalTrials.gov